Table 2.
Prevalence of antifolate resistance mutations in studies on the effect of cotrimoxazole prophylactic treatment (CPT) on malaria incidence.
| Study | Thera et al. | Gasasira et al. | Sandison et al. | Dow et al.* | Ezeamama et al.* |
|---|---|---|---|---|---|
| Country | Mali | Uganda | Uganda | Malawi | Tanzania |
| Study period | 2000 | 2005–06 | 2007–08 | 2004–09 | 2004–08 |
| DHPS gene mutations | |||||
| Gly-437 (437G) | 38% | 96% | 100% | 96% | 77% |
| Glu-540 (540E) | 0% | 97% | 100% | 98% | 71% |
*
Estimates for Dow et al. and Ezeamama et al. were obtained from modeled data provided by the World Wide Antimalarial Resistance Network. For details of the data used in the model see WWARN's Molecular Surveyor (http://www.wwarn.org/surveyor/) and http://www.drugresistancemaps.org.
DHPS: dihydropteroate synthase